CN103820357A - Long bifidobacterium and function thereof for prevention and treatment of food allergy - Google Patents
Long bifidobacterium and function thereof for prevention and treatment of food allergy Download PDFInfo
- Publication number
- CN103820357A CN103820357A CN201310745868.XA CN201310745868A CN103820357A CN 103820357 A CN103820357 A CN 103820357A CN 201310745868 A CN201310745868 A CN 201310745868A CN 103820357 A CN103820357 A CN 103820357A
- Authority
- CN
- China
- Prior art keywords
- onlly
- bifidus longum
- long bifidobacterium
- bifidus
- longum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a long bifidobacterium and the function thereof for the prevention and treatment of food allergy. The preservation number of the long bifidobacterium in China General Microbiological Culture Collection Center is CGMCC No.2107. The long bifidobacterium does not contain drug resistance genes of exogenous antibiotics, so that the long bifidobacterium is safe to eat. The acid resistance of the long bifidobacterium is obviously better than that of common bacterial strains, the bile salt resistance of the long bifidobacterium is obviously better than that of the common bacterial strains, and the fermentability of the long bifidobacterium is obviously better than that of the common bacterial strains..
Description
Invention field
The present invention relates to a kind of new bacterial strain and application thereof of genus bifidobacterium, more precisely, the invention describes a new bacterial strain BL88-ONLLY of bifidus longum bb (Bifidobacterium longum), CGMCC No.2107, CNCM I-4456, and the probiotic bacterium performance of advantage.The invention still further relates to the function that bifidus longum bb BL88-ONLLY has the food anaphylaxis of preventing and treating.
Background technology
Bifidus bacillus is the maximum bacterium of content in human intestine, can reach 10～10,000,000,000/gram, and metabolism and health to host play a crucial role.Wherein bifidus longum bb (Bifidobacterium longum) is a kind of bifidus bacillus the most extensively existing at human body, in all age group crowd, is all found.Although the biological safety of people source bifidus bacillus is higher, prebiotic performance is better, but people source bifidus bacillus is as bifidus longum bb, not tally bifid, baby's bifid, (the pH2.0 under simulated gastric fluid condition such as youth bifid and short bifid, 90min) all do not demonstrate intrinsic sour tolerance (Matto, J., Alakomi, HL.et al.Influence of processing conditions on bifidobacterium animalis subsp, lactis functionality with a special focus on acid tolerance and factors affecting it.International Dairy Journal, 16:1029-1037, 2006), the characteristic limitations that poor, the leavening property of acid tolerance is weak the application of bifidus longum bb.Therefore, taming advantage acid resistance, bile tolerance performance and the high leavening property of specific bacterial strain, is the prerequisite that bifidus longum bb can commercial application.
In recent years, along with the improvement of environmental health situation, children especially newborn infant to be exposed to the probability of microorganism more and more lower, cause newborn infant's body immune system developmental immaturity, immunologic function disorder, cause thus the incidence of food anaphylaxis and other anaphylactic diseases to rise.It is generally acknowledged, when food anaphylaxis, intestinal microflora changes, and intestinal mucosa barrier destroys, simultaneously with inflammatory reaction in various degree.Bacterium lacticum and bifidus bacillus, as a kind of enteron aisle fungal component, can, by regulating flora ratio, strengthen intestinal mucosa barrier function, reduce the release of inflammatory mediator, and the function of the many-side preventions such as induction oral tolerance and treatment food anaphylaxis more and more causes concern.
There are some researches show, the generation that lactobacillus rhamnosus (Lactobacillus rhamnosus) LGG can lower irritated baby's antibody IgE, alleviate symptom (the Viljanen M of milk allergy allergic dermatitis, Savilahti E, Haahtela T, et al.Probiotics in the treatment of atopic eczema/dermatitis syndrome in infants:a double-blind placebo-controlled trial.Allergy, 2005,60 (4): 494-500).In addition, studies have found that, as mouse stomach oralbumin one Toxins,exo-, cholera (Ovalbumin.Cholera toxin.OVA-CT) when induced hypersensitivity, give bifidumbacterium bifidum (Bifidobacterium bifidum) BGN4 and lactobacterium casei (Lactobacillus casei) 911 o'clock, its OVA-specific IgE, total IgE and IgG1 reduce, symptom on mastocyte threshing and mouse tail alleviates to some extent, this shows that bifidumbacterium bifidum BGN4 and lactobacterium casei 911 can prevent and treat food anaphylaxis (Kim H, Kwack K, Kim DY, et al.Oral probiotic bacterial administration suppressed allergic responses in an ovalbumin-induced allergy mouse model.FEMS Immunology and Medical Microbiology, 2005, 45 (2): 259-267).
But not all Bacterium lacticum and bifidus bacillus all have preventive and therapeutic action to food anaphylaxis, because the function of probiotic bacterium has bacterial strain specificity, therefore, only have specific bacterial strain just to there is the function that suppresses food anaphylaxis.
Summary of the invention
In view of above problem, the object of this invention is to provide a strain bifidus longum bb (Bifidobacterium longum) BL88-ONLLY, CGMCC No.2107, CNCM I-4456, and the probiotic bacterium performance of advantage, especially, have the food anaphylaxis of control function.Its sequence table is as appended subsequently.
The solution that realizes foregoing invention object is:
One strain bifidus longum bb (Bifidobacterium longum) BL88-ONLLY, this bacterial strain separated from healthy infants ight soil in August, 2004, and former bacterial strain number is Ba1, and its 16S rRNA Gene Partial sequence is AY766412 in the accession number of GeneBank.Respectively on July 13rd, 2007 and on March 28th, 2011 at Chinese common micro-organisms culture presevation administrative center (China General Microbiological Culture Collection Center, be called for short CGMCC, address is: Yard 1, BeiChen xi Road, Chaoyang District, Beijing City, Institute of Microorganism, Academia Sinica) (original name is called China Committee for Culture Collection of Microorganisms's common micro-organisms center, raw address: Datun Road, Chaoyang District, Beijing City Institute of Microorganism, Academia Sinica) and French microbial strains preservation center (Collection Nationale De Cultures De Microorganisms, be called for short CNCM) preservation, preservation registration number is respectively CGMCC NO.2107 and CNCM I-4456.
Bifidus longum bb BL88-ONLLY, not containing external source antibiotics resistance gene, edible safety.
Bifidus longum bb BL88-ONLLY, its production need be through the domestication of 0.2% cholate, low acid (pH3.0) and 0.05% hydrogen peroxide with bacterial strain.
Bifidus longum bb BL8-ONLLY, it is obviously better than common bacterial strain to sour tolerance performance.
Bifidus longum bb BL88-ONLLY, its tolerance performance to biliary salts is obviously better than common bacterial strain.
Bifidus longum bb BL88-ONLLY, its leavening property is obviously better than common bacterial strain.
Bifidus longum bb BL88-ONLLY, can be by strengthening food anaphylaxis Rats ' Intestinal Mucosal immunologic function, lowers the level of Th2 cytokines to regulate Th1/Th2 balance, has the function of the food anaphylaxis of preventing and treating.
Embodiment
Bifidus longum bb BL88-ONLLY of the present invention separated from healthy infants ight soil in August, 2004, and former bacterial strain number is Ba1, and its 16S rRNA Gene Partial sequence is AY766412 in the accession number of GeneBank.Its form is shaft-like, and Gram-positive does not form gemma, catalase feminine gender, and oxidase negative, F6PPK enzyme positive, strictly anaerobic growth, produces lactic acid.
Table 1 bifidus longum bb BL88-ONLLY carbohydrate utilizes situation
| Test subject | Result | Test subject | Result |
| Glucose | + | Seminose | + |
| Sunmorl N 60S | - | N.F,USP MANNITOL | - |
| Cellobiose | - | Maltose | + |
| Wood sugar | + | Sorbyl alcohol | - |
| Fructose | + | Melibiose | + |
| Ribose | + | Semi-lactosi | + |
| Raffinose | + | Pectinose | + |
| Lactose | + | Sucrose | + |
| Melizitose | + | Trehalose | - |
| Salicin | - | Starch | - |
| Synanthrin | - | ? | ? |
The culturing process of bifidus longum bb BL88-ONLLY of the present invention: cultivate 24h for 37 ℃ in MRSC liquid nutrient medium (add in MRS 0.05% cysteine hydrochloride).
Bifidus longum bb BL88-ONLLY of the present invention, respectively on July 13rd, 2007 and on March 28th, 2011 at China Committee for Culture Collection of Microorganisms's common micro-organisms center (China General Microbiological Culture Collection Center, and French pasteur microbial strains preservation center (Collection Nationale De Cultures De Microorganisms CGMCC), CNCM) preservation, preservation registration number is respectively CGMCC NO.2107 and CNCM I-4456.
Further illustrate the present invention below in conjunction with embodiment:
The antibiotic sensitive performance of embodiment 1 bifidus longum bb BL88-ONLLY
Adopt SN/T1944-2007 " mensuration of bacterial drug resistance in animal and goods thereof " method, the antibiotic sensitive performance of assessment bifidus longum bb BL8-ONLLY, evaluation result refers to following table.
Table 2 bifidus longum bb BL88-ONLLY antibiotic drug sensitive is evaluated
| Microbiotic title | Susceptibility | Microbiotic title | Susceptibility |
| 1 penicillin P-G | S | 10 kantlex KAN | MS |
| 2 Ampicillin Trihydrate AMP | S | 11 Streptomycin sulphate STR | R |
| 3 penbritins/Sulbactam AMS | S | 12 tobramycin TOB | R |
| 4 clindamycin CLI | S | 13 cefepime CPI | S |
| 5 paraxin CMP | S | 14 rocephin CRO | S |
| 6 tsiklomitsin TET | S | 15 ceftazime CTD | S |
| 7 vancomycin VAN | S | 16 cefotaxime CTX | S |
| 8 Erythromycin E RY | S | 17 ceftizoxime CTZ | MS |
| 9 gentamicin GEN | R | 18 cefoxitin CXT | S |
Upper table result shows, bifidus longum bb BL8-ONLLY, to sensitivities such as Ampicillin Trihydrate Ampicillin, penicillin G Penicillin G etc., Erythromycin E rythromycin, paraxin Chloramphenicol, clindamycin Clindamycin, vancomycin Vancomycin and tsiklomitsin Tetracycline, has plant resistance to aminoglycosides antibiotics such as gentamicin Gentamicin, kantlex Kanamycin, Streptomycin sulphate Streptomycin.Meet the European food safety council (European Food Safety Authority) to requirement (the Technical guidance in edible bacterial drug resistance value disciplines, Update of the criteria used in the assessment of bacterial resistance to antibiotics of human or veterinary importance, The EFSA Journal2008:732,1-15).
Conclusion: bifidus longum bb BL88-ONLLY does not contain external source antibiotics resistance gene, edible safety.
Embodiment 2 bifidus longum bb BL88-ONLLY produce the domestication with bacterial classification
Renewal cultivation: get 0.4mlMRSC liquid nutrient medium, splash in the ampoul tube that bifidus longum bb BL88-ONLLY freeze-dried vaccine powder is housed, vibration gently, dissolves freeze-drying thalline and be suspension; This thallus suspension liquid is injected in 14mlMRSC liquid nutrient medium, and anaerobism is cultivated 24 hours at 37 ℃.
Acclimation: the bacterium liquid 1ml that gets above-mentioned renewal cultivation is seeded to 13ml containing in the MRSC substratum of 0.2% cholate, 24～48 hours anaerobism are cultivated at 37 ℃, for carrying out next step domestication.Get again above-mentioned cultured bacterium liquid 1ml and be seeded in the MRSC liquid nutrient medium test tube that 13ml pH value is 3.0, mix rear 37 ℃ of anaerobic treatment 3 hours.Draw the acidproof bacterium liquid 1ml after treatment of above-mentioned process and be seeded to 13ml containing in the MRSC substratum of 0.05% hydrogen peroxide H2O2, mix rear 37 ℃ of anaerobic treatment 2 hours.
Domesticated strain: get the above-mentioned bacterium liquid 1ml through acclimation, with physiological saline gradient dilution, more respectively with different concns diluent 0.1ml coating MRSC Solid agar culture, 37 ℃ of anaerobism are cultivated 48～72 hours.Choose the flat board of colony number between 30～300, picking list colony inoculation is to 10ml MRSC liquid nutrient medium, and 37 ℃ of anaerobism are cultivated 24 hours.After cultivation, cultivate a generation again with 1% inoculum size similarity condition, then draw nutrient solution 0.5ml and prepare glycerine pipe, domesticated strain is as production bacterial classification.
Embodiment 3 bifidus longum bb BL88-ONLLY have the acid resistance of advantage
Bacterial classification to be evaluated is seeded in MRSC liquid nutrient medium, at 37 ℃, be cultured to 24h, centrifugal 10min under 4 ℃, 2500rpm, collect thalline, after phosphate buffered saline buffer (PBS) washing, be resuspended in PBS, get the resuspended liquid of 1.0ml cell and to pH be in 3.0,2.0 the aseptic PBS of 9.0ml, process after 0,1 hour for 37 ℃ and carry out live bacterial count.Evaluate the acid resistance of bacterial strain with survival rate, survival rate=(viable count/0 moment viable count after treatment) x100%.The present embodiment adopt separation that laboratory preserves from the bifidus longum bb SQS4-64 of commercially produced product through above-mentioned bacterial classification after the acclimation of bacterial classification for same production, bacterial strain in contrast.
The acid resistance (pH=2.0 processes 1h) of table 3 bifidus longum bb BL88-ONLLY advantage
The acid resistance (pH=3.0 processes 1h) of table 4 bifidus longum bb BL88-ONLLY advantage
Conclusion: bifidus longum bb BL88-ONLLY, the more common bacterial strain of its bile tolerance performance has a clear superiority in.
Embodiment 4 bifidus longum bb BL88-ONLLY have the bile tolerance performance of advantage
By bacterial strain to be evaluated in MRSC liquid nutrient medium, at 37 ℃, be cultured to 24h, centrifugal 10min under 4 ℃, 2500rpm, collect thalline, after phosphate buffered saline buffer (PBS) washing, be resuspended in PBS, get the resuspended liquid of 1.0ml cell to gallbladder salinity and be 0, in the 9.0ml PBS of 0.3%. (w/v), carry out live bacterial count analysis in 37 ℃ after processing 3 hours, 24 hours.Evaluate the bile tolerance performance of bacterial strain with survival rate, survival rate=(viable count/0 moment viable count after treatment) x100%.The present embodiment adopt separation that laboratory preserves from the bifidus longum bb SQS4-64 of commercially produced product through above-mentioned bacterial classification after the acclimation of bacterial classification for same production, bacterial strain in contrast.
The bile tolerance performance (0.3% cholate is processed 3h) of table 5 bifidus longum bb BL88-ONLLY advantage
The bile tolerance performance (0.3% cholate is processed 24h) of table 6 bifidus longum bb BL88-ONLLY advantage
Conclusion: bifidus longum bb BL88-ONLLY, the more common bacterial strain of its bile tolerance performance has a clear superiority in.
Embodiment 5 bifidus longum bb BL88-ONLLY have the leavening property of advantage
Bacterial strain to be evaluated, in MRSC liquid nutrient medium, is carried out to live bacterial count after being cultured to 24h at 37 ℃.The present embodiment adopt separation that laboratory preserves from the bifidus longum bb SQS4-64 of commercially produced product through above-mentioned bacterial classification after the acclimation of bacterial classification for same production, bacterial strain in contrast.
The leavening property of table 7 bifidus longum bb BL88-ONLLY advantage
Conclusion: bifidus longum bb BL88-ONLLY production bacterial classification, the more common bacterial strain of its leavening property has a clear superiority in.
Embodiment 6 bifidus longum bb BL88-ONLLY have the function of the food anaphylaxis of preventing and treating
Take BL88-ONLLY as starting strain, obtain production bacterial classification through domestication, then be experiment material through the BL88-ONLLY freeze-dried vaccine powder (viable count is greater than 1,000 hundred million/gram) fermenting, centrifugal, lyophilize is made.
The female Brown-Norway children mouse of weaning 3 week age is divided into blank group, food anaphylaxis group and BL88-ONLLY intervention group, 10 every group at random.Adopt ovalbumin (Ovalbumin, OVA) to induce young mouse to produce food anaphylaxis model.Blank group, adopts physiological saline 1ml/d gavage, continues 6 weeks.Food anaphylaxis group, adopts 1mg/ml OVA solution 1ml/d gavage, continues 6 weeks.BL88-ONLLY intervention group, adopts 1mg/ml OVA solution 1ml/d gavage, gives BL88-ONLLY lyophilized powder suspension oral gavage simultaneously, and dosage is 1,000,000,000/d, continues 6 weeks.
After the last day, gavage finished, animal fasting 12h, the 200mg/ml OVA solution gavage that every rat gives 1ml afterwards excites, and after 1.5h, with the vetanarcol intraperitoneal injection of anesthesia of 50mg/kg weight, gets blood.After open abdomen and get small intestine contents 0.1g, with 1ml normal saline dilution, mix, centrifugal, get supernatant ,-20 ℃ of preservations are to be checked.Meanwhile, do not get spleen at aseptic condition, carry out immediately cellular segregation.
Adopt ELISA test kit to detect serum OVA-IgE level, small intestine contents sIgA level and respectively organize splenic lymphocyte and stimulate the sub-IL-4 level of cellular water in supernatant liquor.
Stimulate the sub-IL-4 level of cellular water in supernatant liquor from respectively organize OVA-IgE in serum, small intestine contents sIgA and splenic lymphocyte as following table 8(), the OVA-IgE antibody horizontal of food anaphylaxis group, higher than blank group, shows to adopt the success of OVA sensitized rats.And after bifidus longum bb BL88-ONLLY intervention, can significantly reduce serum OVA-IgE level, prompting BL88-ONLLY can reduce the generation of OVA-IgE, alleviates the generation of I type allergy.And the intestinal contents sIgA level of BL88-ONLLY intervention group is apparently higher than food anaphylaxis group and blank group, and prompting BL88-ONLLY has protection intestinal immunological barrier function, thereby improves food anaphylaxis.Relatively splenic lymphocyte stimulates the level of IL-4 in supernatant liquor to find, BL88-ONLLY organizes significantly lower than food anaphylaxis group, and close to blank group, prompting, in the food anaphylaxis process of OVA induction, BL88-ONLLY regulates Th1/Th2 balance to Th1 direction polarization by suppressing the reaction of Th2 type.
Table 8
| Group | OVA-IgE(μg/ml) | sIgA(ng/ml) | IL-4(ng/ml) |
| Blank group | 2.35±0.32 | 132.65±25.32 | 78.45±31.26 |
| Food anaphylaxis group | 4.56±1.25 * | 136.58±45.34 | 392.45±156.31 * |
| BL88-ONLLY intervention group | 2.01±0.95 Δ | 325.69±134.20 *Δ | 76.34±38.25 Δ |
*p < 0.05 and the comparison of blank group;
Δp < 0.05 and the comparison of food anaphylaxis group.
Conclusion: bifidus longum bb BL88-ONLLY can be by strengthening food anaphylaxis Rats ' Intestinal Mucosal immunologic function, lowers the level of Th2 cytokines to regulate Th1/Th2 balance, has the function of the food anaphylaxis of preventing and treating.
Claims (4)
1. a strain bifidus longum bb, is characterized in that, described bifidus longum bb is CGMCC NO.2107 at the deposit number of Chinese common micro-organisms culture presevation administrative center.
2. bifidus longum bb according to claim 1, is characterized in that, the production of described bifidus longum bb need be through the domestication of the hydrogen peroxide of 0.2% cholate, low acid that pH is 3.0 and 0.05% with bacterial strain.
3. the bifidus longum bb described in claim 1 or 2 is in the application preventing and treating in food anaphylaxis.
4. application according to claim 3, described bifidus longum bb is not containing external source antibiotics resistance gene.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310745868.XA CN103820357A (en) | 2013-12-30 | 2013-12-30 | Long bifidobacterium and function thereof for prevention and treatment of food allergy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310745868.XA CN103820357A (en) | 2013-12-30 | 2013-12-30 | Long bifidobacterium and function thereof for prevention and treatment of food allergy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103820357A true CN103820357A (en) | 2014-05-28 |
Family
ID=50755651
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310745868.XA Pending CN103820357A (en) | 2013-12-30 | 2013-12-30 | Long bifidobacterium and function thereof for prevention and treatment of food allergy |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103820357A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105176857A (en) * | 2014-06-12 | 2015-12-23 | 暨南大学 | Lactic acid bacteria having ampicillin resistance, and preparation and applications of preparation of lactic acid bacteria having ampicillin resistance |
| CN108410763A (en) * | 2018-03-14 | 2018-08-17 | 浙江同创越诚健康科技有限公司 | Bifidobacterium longum TC01 and its application and apply its product |
| CN112159784A (en) * | 2020-10-29 | 2021-01-01 | 佛山市朗芯生物科技有限公司 | Bifidobacterium longum NX-4 and application thereof in preparing medicament for treating and/or preventing allergic diseases |
| CN113908176A (en) * | 2021-11-30 | 2022-01-11 | 浙江工商大学 | Composition for preventing and treating food allergy |
| CN118240715A (en) * | 2024-05-29 | 2024-06-25 | 善恩康生物科技（苏州）有限公司 | Bifidobacterium longum and application thereof in relieving allergy |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101099749A (en) * | 2007-07-25 | 2008-01-09 | 上海交大昂立股份有限公司 | Composition containing lactobacillus acidophilus and bidifobacterium longum and application thereof |
| CN101420965A (en) * | 2006-02-15 | 2009-04-29 | 雀巢产品技术援助有限公司 | The purposes of bifidobacterium longum in prevention and treatment inflammation |
| CN101688171A (en) * | 2007-03-28 | 2010-03-31 | 营养健康有限公司 | probiotic bifidobacterium strains |
| CN102159085A (en) * | 2008-09-19 | 2011-08-17 | 美赞臣营养品公司 | Probiotic infant products |
| CN102899261A (en) * | 2011-03-11 | 2013-01-30 | 光晟生物科技股份有限公司 | Bifidobacterium longum subspecies longum isolate producing high immune activation response and composition capable of stimulating immune activation |
| CN102905557A (en) * | 2009-08-18 | 2013-01-30 | 雀巢产品技术援助有限公司 | A nutritional composition comprising bifidobacterium longum strains and reducing food allergy symptoms, especially in infants and children |
-
2013
- 2013-12-30 CN CN201310745868.XA patent/CN103820357A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101420965A (en) * | 2006-02-15 | 2009-04-29 | 雀巢产品技术援助有限公司 | The purposes of bifidobacterium longum in prevention and treatment inflammation |
| CN101688171A (en) * | 2007-03-28 | 2010-03-31 | 营养健康有限公司 | probiotic bifidobacterium strains |
| CN101099749A (en) * | 2007-07-25 | 2008-01-09 | 上海交大昂立股份有限公司 | Composition containing lactobacillus acidophilus and bidifobacterium longum and application thereof |
| CN102159085A (en) * | 2008-09-19 | 2011-08-17 | 美赞臣营养品公司 | Probiotic infant products |
| CN102905557A (en) * | 2009-08-18 | 2013-01-30 | 雀巢产品技术援助有限公司 | A nutritional composition comprising bifidobacterium longum strains and reducing food allergy symptoms, especially in infants and children |
| CN102899261A (en) * | 2011-03-11 | 2013-01-30 | 光晟生物科技股份有限公司 | Bifidobacterium longum subspecies longum isolate producing high immune activation response and composition capable of stimulating immune activation |
Non-Patent Citations (3)
| Title |
|---|
| BORJA SÁNCHEZ等: "Low-pH Adaptation and the Acid Tolerance Response of Bifidobacterium longum Biotype longum", 《APPLIED AND ENVIRONMENTAL MICROBIOLOGY》 * |
| M.-M. GRÖNLUND等: "Maternal breast-milk and intestinal bifidobacteria guide the compositional development of the Bifidobacterium microbiota in infants at risk of allergic disease", 《CLINICAL AND EXPERIMENTAL ALLERGY》 * |
| NORIYUKI IWABUCHI等: "In Vitro Th1 Cytokine-Independent Th2 Suppressive Effects of Bifidobacteria", 《MICROBIOLOGY AND IMMUNOLOGY》 * |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105176857A (en) * | 2014-06-12 | 2015-12-23 | 暨南大学 | Lactic acid bacteria having ampicillin resistance, and preparation and applications of preparation of lactic acid bacteria having ampicillin resistance |
| CN105176857B (en) * | 2014-06-12 | 2019-02-12 | 暨南大学 | The preparation and application of bifidobacterium longum and its preparation with amicillin resistance |
| CN108410763A (en) * | 2018-03-14 | 2018-08-17 | 浙江同创越诚健康科技有限公司 | Bifidobacterium longum TC01 and its application and apply its product |
| CN108410763B (en) * | 2018-03-14 | 2020-10-09 | 绍兴同创生物科技有限公司 | Bifidobacterium longum TC01 and application and product using same |
| CN112159784A (en) * | 2020-10-29 | 2021-01-01 | 佛山市朗芯生物科技有限公司 | Bifidobacterium longum NX-4 and application thereof in preparing medicament for treating and/or preventing allergic diseases |
| CN113908176A (en) * | 2021-11-30 | 2022-01-11 | 浙江工商大学 | Composition for preventing and treating food allergy |
| CN113908176B (en) * | 2021-11-30 | 2024-02-09 | 浙江工商大学 | Composition for preventing and treating food allergy |
| CN118240715A (en) * | 2024-05-29 | 2024-06-25 | 善恩康生物科技（苏州）有限公司 | Bifidobacterium longum and application thereof in relieving allergy |
| CN118240715B (en) * | 2024-05-29 | 2024-09-20 | 善恩康生物科技（苏州）有限公司 | Bifidobacterium longum and application thereof in relieving allergy |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102206599B (en) | Oxygen-resistant acid-resistant Bifidobacterium longum | |
| CN114317320B (en) | Bifidobacterium breve 207-1 and application thereof | |
| US20200009202A1 (en) | Bacterial composition and its use | |
| CN101688171B (en) | Probiotic bifidobacterium strains | |
| US20040110270A1 (en) | Bacterial composition and its use | |
| Tomičić et al. | Beneficial properties of probiotic yeast Saccharomyces boulardii | |
| NZ248057A (en) | Bifidobacterium strains and pharmaceutical compositions containing them | |
| CN102618456A (en) | Lactobacillus rhamnosus capable of relieving chronic alcohol liver injury and application thereof | |
| CN103114051A (en) | Roy bacterium lacticum and application thereof | |
| CN101366734A (en) | Synbiotics medicament composition | |
| CN103820357A (en) | Long bifidobacterium and function thereof for prevention and treatment of food allergy | |
| TW200406216A (en) | Novel acid-and bile salt-resistant Lactobacillus isolates having the ability to lower and assimilate cholesterol | |
| CN103540545A (en) | Pediococcus pentosaceus and application thereof | |
| CN103031263A (en) | Lactobacillus rhamnosus, cultivation of lactobacillus rhamnosus and microcapsule method | |
| CN113832077A (en) | Lactobacillus rhamnosus and application thereof | |
| CN109022313B (en) | Lactobacillus plantarum | |
| CN114990030B (en) | Lactobacillus acidophilus LA18 and application thereof in preparing product for regulating intestinal flora or immunoregulation | |
| JP2004305128A (en) | Feed composition | |
| CN117568211A (en) | Lactobacillus plantarum GOLDGUT-LP618 with salmonella infection resistance function and application thereof | |
| de Rezende Rodovalho et al. | Propionibacterium freudenreichii: General characteristics and probiotic traits | |
| CN110438042A (en) | One plant of bifidobacterium longum and its application | |
| CN111685255B (en) | Probiotic solid beverage for enhancing immune function and preparation method thereof | |
| US20220313756A1 (en) | Method for alleviating helicobacter pylori-associated disorder using culture of lactic acid bacterial strain | |
| Szabo-Fodor et al. | Physiological effects of whey-and milk-based probiotic yogurt in rats | |
| JP2010057395A (en) | Lactic acid bacterium having enteric canal immunomodulating action |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140528 |